Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Updated CLL guidelines

Hallek M et al. Blood https://doi.org/10.1182/blood-2017-09-806398

Major changes or additions to new guidelines for chronic lymphocytic leukemia include the following:

Molecular genetics: Recognition of the clinical importance of specific genomic alterations/mutations 17p deletion and mutations in TP53 on therapeutic response.

IGHV mutational status: Immunoglobulin variable heavy chain (IGHV) genes offer important prognostic information.

Biomarkers: Soluble CD23, thymidine kinase, and beta-2-microglobulin need to be standardized and used in prospective clinical trials.

MRD: Minimal residual disease should be assessed in clinical trials aimed at maximizing remission depth.

Antiviral prophylaxis: Patients should be tested for HBV serological status before starting on an anti-CD20 agent.

Read the article.

Citation:

Hallek M et al. Blood https://doi.org/10.1182/blood-2017-09-806398